Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00 at Citizens Jmp

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective upped by equities research analysts at Citizens Jmp to $25.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price target would indicate a potential upside of 91.57% from the stock’s previous close.

Several other research firms also recently commented on ZVRA. Guggenheim raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings cut Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald increased their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.17.

Zevra Therapeutics Stock Performance

ZVRA opened at $13.05 on Tuesday. The stock’s 50 day moving average price is $10.37 and its 200-day moving average price is $9.39. Zevra Therapeutics has a one year low of $7.16 and a one year high of $13.16. The stock has a market cap of $771.52 million, a price-to-earnings ratio of 6.49 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. As a group, analysts predict that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC lifted its stake in shares of Zevra Therapeutics by 12.3% during the 4th quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock worth $114,000 after purchasing an additional 1,390 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Zevra Therapeutics by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock valued at $179,000 after purchasing an additional 1,750 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after purchasing an additional 1,812 shares in the last quarter. Deutsche Bank AG raised its holdings in Zevra Therapeutics by 4.4% in the fourth quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock worth $412,000 after purchasing an additional 1,936 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in shares of Zevra Therapeutics by 10.5% during the fourth quarter. MetLife Investment Management LLC now owns 27,867 shares of the company’s stock valued at $250,000 after buying an additional 2,653 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.